新型青霉素BRL 36650的体外活性
In vitro activity of BRL 36650, a new penicillin.
作者信息
Van Landuyt H W, Lambert A, Boelaert J, Gordts B
出版信息
Antimicrob Agents Chemother. 1986 Feb;29(2):362-6. doi: 10.1128/AAC.29.2.362.
Abstract
Compared with four beta-lactam antibiotics and amikacin, BRL 36650 and BMY-28142 were the most active against 509 Enterobacteriaceae, including cefotaxime-resistant isolates and resistant laboratory mutants. BRL 36650 was more active than aztreonam, ceftazidime, and BMY-28142 against Acinetobacter spp., Pseudomonas aeruginosa, and other Pseudomonas spp.; all strains were inhibited by 2 micrograms/ml or less.
摘要
与四种β-内酰胺类抗生素和阿米卡星相比，BRL 36650和BMY - 28142对509株肠杆菌科细菌活性最强，包括耐头孢噻肟菌株和耐药实验室突变株。BRL 36650对不动杆菌属、铜绿假单胞菌和其他假单胞菌属的活性比氨曲南、头孢他啶和BMY - 28142更强；所有菌株均被2微克/毫升或更低浓度抑制。
相似文献
1
In vitro activity of BRL 36650, a new penicillin.新型青霉素BRL 36650的体外活性
Antimicrob Agents Chemother. 1986 Feb;29(2):362-6. doi: 10.1128/AAC.29.2.362.
2
In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolates.卡芦莫南（RO 17-2301）、BMY-28142、氨曲南和头孢他啶对7620株连续临床分离细菌的体外活性。
Diagn Microbiol Infect Dis. 1986 Nov;5(4):345-9. doi: 10.1016/0732-8893(86)90041-6.
3
In vitro activity of ceftazidime, cefotaxime and piperacillin against multi-resistant gram-negative bacteria tested with a modified agar dilution method.用改良琼脂稀释法检测头孢他啶、头孢噻肟和哌拉西林对多重耐药革兰氏阴性菌的体外活性。
Eur J Clin Microbiol. 1982 Jun;1(3):166-70. doi: 10.1007/BF02019618.
4
Belgian multicentre study on the in vitro activity of cefepime against gram-negative bacilli.比利时关于头孢吡肟对革兰氏阴性杆菌体外活性的多中心研究。
Acta Clin Belg. 1996;51(1):28-35.
5
Comparative in vitro activity of cefepime against nosocomial isolates.头孢吡肟对医院感染分离株的体外活性比较
J Chemother. 1997 Oct;9(5):341-6. doi: 10.1179/joc.1997.9.5.341.
6
In vitro activities of antibiotic combinations against clincal isolates of Pseudomonas aeruginosa.抗生素组合对铜绿假单胞菌临床分离株的体外活性
Kaohsiung J Med Sci. 2004 Jun;20(6):261-7. doi: 10.1016/s1607-551x(09)70116-0.
7
In-vitro activity of BRL-36650, a novel beta-lactamase-stable penicillin, against multiply resistant gram-negative organisms.
J Antimicrob Chemother. 1986 Sep;18(3):351-8. doi: 10.1093/jac/18.3.351.
8
In vitro antibacterial properties of BRL 36650, a novel 6 alpha-substituted penicillin.新型6α-取代青霉素BRL 36650的体外抗菌特性
Antimicrob Agents Chemother. 1984 Nov;26(5):734-40. doi: 10.1128/AAC.26.5.734.
9
Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group.使用Etest方法对哥伦比亚六种广谱β-内酰胺类抗生素的耐药性进行多中心评估。哥伦比亚抗菌药物耐药性研究小组。
Diagn Microbiol Infect Dis. 1997 Dec;29(4):265-72. doi: 10.1016/s0732-8893(97)00157-0.
10
Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.头孢吡肟（BMY 28142）对多重耐药医院分离铜绿假单胞菌的体外活性比较
Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):917-9. doi: 10.1007/BF01963783.
引用本文的文献
1
Cefepime clinical pharmacokinetics.头孢吡肟的临床药代动力学。
Clin Pharmacokinet. 1993 Aug;25(2):88-102. doi: 10.2165/00003088-199325020-00002.
2
Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.头孢吡肟：抗菌活性、药代动力学特性及治疗用途综述
Drugs. 1994 Mar;47(3):471-505. doi: 10.2165/00003495-199447030-00007.
本文引用的文献
1
In vitro activity of temocillin (BRL 17421), a novel beta-lactam antibiotic.新型β-内酰胺抗生素替莫西林（BRL 17421）的体外活性
Antimicrob Agents Chemother. 1982 Oct;22(4):535-40. doi: 10.1128/AAC.22.4.535.
2
BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.BRL 17421是一种新型β-内酰胺抗生素，对β-内酰胺酶具有高度抗性，在人体内可产生高且持久的血清浓度。
Antimicrob Agents Chemother. 1981 Jul;20(1):38-46. doi: 10.1128/AAC.20.1.38.
3
In vitro antibacterial properties of BRL 36650, a novel 6 alpha-substituted penicillin.新型6α-取代青霉素BRL 36650的体外抗菌特性
Antimicrob Agents Chemother. 1984 Nov;26(5):734-40. doi: 10.1128/AAC.26.5.734.
4
Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future.新型β-内酰胺类抗生素治疗期间耐药性的出现：诱导性β-内酰胺酶的作用及对未来的影响。
Rev Infect Dis. 1983 Jul-Aug;5(4):639-48. doi: 10.1093/clinids/5.4.639.
5
Chromosomal beta-lactamases of Enterobacter cloacae are responsible for resistance to third-generation cephalosporins.阴沟肠杆菌的染色体β-内酰胺酶是导致对第三代头孢菌素耐药的原因。
Antimicrob Agents Chemother. 1983 Jun;23(6):918-25. doi: 10.1128/AAC.23.6.918.
6
In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin.新型广谱头孢菌素BMY-28142的体外抗菌活性
Antimicrob Agents Chemother. 1985 Apr;27(4):574-7. doi: 10.1128/AAC.27.4.574.
7
In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.BMY-28142与其他β-内酰胺类抗菌剂相比的体外活性。
Antimicrob Agents Chemother. 1985 Apr;27(4):515-9. doi: 10.1128/AAC.27.4.515.
Zotero 插件